Journal article
Outcomes of Women Who Were Premenopausal at Diagnosis of Early Stage Breast Cancer in the NCIC CTG MA17 Trial.
Abstract
Abstract
Background: MA17 showed that adjuvant letrozole after 5 years of tamoxifen markedly reduced the risk of recurrence in women with ER+ early stage breast cancer and improved overall survival in women presenting with node +ve disease. Most trials of early adjuvant aromatase inhibitor therapy required women to be postmenopausal at diagnosis to be eligible. We report here on a subset of women in the MA17 trial who were …
Authors
Goss P; Ingle J; Martino S; Robert N; Muss H; Shepherd L; Pritchard K; Livingston R; Davidson N; Perez E
Journal
Cancer Research, Vol. 69, No. 24_Supplement, pp. 13–13
Publisher
American Association for Cancer Research (AACR)
Publication Date
December 15, 2009
DOI
10.1158/0008-5472.sabcs-09-13
ISSN
0008-5472